Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3036895 | 0.93 | CYP3A4 (0.54) | CYP3A4CACNA1BNR1I2EPHX2MEN1 | |
| SCHEMBL3040847 | 0.82 | CACNA1B (0.61) | CYP3A4CACNA1BNR1I2EPHX2MEN1 | |
| SCHEMBL3035575 | 0.82 | CYP3A4 (0.55) | CYP3A4CACNA1BNR1I2MEN1KMT2A | |
| SCHEMBL15108576 | 0.78 | CACNA1B (0.60) | CYP3A4CACNA1BNR1I2L3MBTL1HPGD | |
| SCHEMBL3038435 | 0.75 | CACNA1B (0.57) | CYP3A4CACNA1BNR1I2KMT2AHPGD | |
| SCHEMBL3030376 | 0.75 | CACNA1B (0.65) | CYP3A4CACNA1BNR1I2HPGDLMNA | |
| SCHEMBL3137781 | 0.74 | EPHX2 (0.48) | EPHX2MEN1KMT2AL3MBTL1HPGD | |
| SCHEMBL15103434 | 0.74 | CACNA1B (0.67) | CYP3A4CACNA1BNR1I2CNR1LMNA | |
| SCHEMBL14701446 | 0.74 | CACNA1B (0.74) | CYP3A4CACNA1BNR1I2 | |
| SCHEMBL8039809 | 0.73 | CACNA1B (0.66) | CYP3A4CACNA1BNR1I2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040932-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | TRPV1, TRPA1, CACNA1D | CYP3A4 939/4885CACNA1B 23/4885NR1I2 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.